Natreon Receives Patent for Ashwagandha Derivative with Possible Alzheimer’s Benefits

September 28, 2015
Michael Crane

The patent covers a group of indolealkylamino-withasteroid conjugates isolated from Ashwagandha.

Natreon (New Brunswick, New Jersey) has received a new patent for a derivative of its Ashwagandha (Withania somnifera) ingredient Sensoril. The patent covers a group of indolealkylamino-withasteroid conjugates isolated from Ashwagandha and purified for “possible treatment of dementia and dementia-related disorders, such as Alzheimer’s Disease, anxiety, and depressive disorders in a patient,” says Natreon.

Early human clinical studies have shown Sensoril to be effective in “decreasing stress levels and improving cognition,” according to Natreon. The company believes the newly patented Sensoril derivative may offer a better option than prescription medication for those suffering from dementia and dementia-related disorders.

“Prescription medications used to treat Alzheimer’s Disease, such as Aricept and Exelon, are marginally effective at best and can have serious side effects,” says Natreon. “Thus, there is a need for a better class of more efficacious drugs without adverse effects. These indolealkylamino-withasteroid conjugates isolated from Withania somnifera may help fill this need.”

 

Read more:

Ashwagandha May Improve Reaction Time

Mood and Relaxation Dietary Supplements: Hope in a Bottle

 

Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com